At what pace is the glioblastoma multiforme market growing, and what is its estimated value?
The glioblastoma multiforme market size has grown strongly in recent years. It will grow from $2.50 billion in 2024 to $2.71 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth in the historic period can be attributed to the increasing incidence of glioblastoma multiforme, rising healthcare infrastructure, increased awareness, increased access to advanced therapies, and growing aging population.
The glioblastoma multiforme market size is expected to see strong growth in the next few years. It will grow to $3.69 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to an increase in cases of brain and other nervous system cancers, increasing acceptability of surgical techniques, rising awareness, early diagnosis of disease, and an increase in the number of R&D activities. Major trends in the forecast period include advances in medical technology, advancements in imaging techniques, personalized medicine, AI for diagnosis, and technological and scientific developments.
Get Your Free Sample of The Global Glioblastoma Multiforme Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21191&type=smp
What are the top drivers to the rising demand in the glioblastoma multiforme market?
The rising brain disorder cases are expected to drive the glioblastoma multiforme market going forward. A brain disorder is a condition that affects the structure or function of the brain, leading to cognitive, emotional, or physical impairments. Rising brain disorder cases are due to factors such as aging populations, increased life expectancy, lifestyle factors, and improved diagnostic capabilities. Understanding brain disorders helps advance research on glioblastoma multiforme (GBM), leading to better early detection, innovative treatments, and improved patient outcomes. By studying neurological conditions, scientists can uncover genetic and molecular links that contribute to GBM development. For instance, in February 2025, according to Dementia Australia, an Australia-based non-profit organization, approximately 433,300 Australians are living with dementia, with this number expected to rise to 812,500 by 2054. Additionally, younger-onset dementia affects around 29,000 people in 2025, with projections indicating an increase to 41,000 by 2054. Therefore, the rising brain disorder cases will drive the growth of the glioblastoma multiforme market.
How is the glioblastoma multiforme market segmented?
The glioblastoma multiforme market covered in this report is segmented –
1) By Drug Class: Chemotherapy Agents, Temozolomide, Carmustine, Lomustine, Other Drug Classes
2) By Diagnostic Tools: Magnetic Resonance Imaging (MRI), Computed Tomography Scan (CT Scan), Biopsy, Other Diagnostic Tools
3) By Treatment Type: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Tumor Treating Field Therapy, Other Treatment Types
4) By End-User: Hospitals, Cancer Research Institutes, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Chemotherapy Agents: Alkylating Agents, Platinum-Based Agents, Antimetabolites
2) By Temozolomide: Branded (Temodar), Generic Temozolomide
3) By Carmustine: Injectable Carmustine, Carmustine Wafers (Gliadel)
4) By Lomustine: Branded (Gleostine), Generic Lomustine
5) By Other Drug Classes: Targeted Therapy, Immunotherapy, Tumor-Treating Fields (TTF) Therapy
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/glioblastoma-multiforme-global-market-report
Who are the top competitors in the glioblastoma multiforme market?
Major companies operating in the glioblastoma multiforme market are Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Eli Lilly and Company, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Zydus Pharmaceuticals (USA) Inc., Accord Healthcare Inc., Sumitomo Dainippon Pharma Oncology Inc., Karyopharm Therapeutics Inc., ITM Isotope Technologies Munich SE, Azurity Pharmaceuticals Inc., Genenta Science S.p.A., Chimeric Therapeutics Limited, VBI Vaccines Inc.
What significant trends should we anticipate in the glioblastoma multiforme market over the forecast period?
Major companies operating in the glioblastoma multiforme market are focusing on developing advanced therapies, such as CAR T-cell therapies, to address the unmet medical needs of aggressive cancer. CAR T-cell therapies are a form of immunotherapy that involves modifying a patient’s T-cells to target and kill cancer cells more effectively. For instance, in June 2023, Chimeric Therapeutics Limited, an Australia-based biotech company, launched a Phase IB clinical trial of CHM 1101 (CLXT CAR T) therapy for recurrent or progressive glioblastoma multiforme (GBM). The trial, conducted at multiple centers, aims to evaluate the therapy’s safety and efficacy while determining the recommended Phase 2 dose. Initial Phase 1a results showed disease stability, and the trial will build on this to support further development. The company plans to use the data to design a registration trial and seek regulatory feedback.
Which regional trends are influencing the glioblastoma multiforme market, and which area dominates the industry?
North America was the largest region in the glioblastoma multiforme market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glioblastoma multiforme market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Glioblastoma Multiforme Market Report 2025 Offer?
The glioblastoma multiforme market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Glioblastoma multiforme (GBM) is an aggressive and fast-growing brain tumor that originates in the glial cells of the brain. It is the lethal form of primary brain cancer, characterized by rapid proliferation and resistance to standard treatments.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21191
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
